Insider Transactions Screener
Search for and identify insider purchases or sales of company shares. The screener offers additional information and analysis on the transactions and allows users to set up alerts and receive notifications when new transactions occur.
| Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
|---|---|---|---|---|---|---|
|
ADBE
|
Shantanu Narayen
Chair and CEO |
SELL
Open market or private sale
|
Indirect | 22,422 Reduced 1.78% |
$1,941,745
$86.6 p/Share
|
Mar 01
2016 |
|
ADBE
|
Shantanu Narayen
Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect | 22,422 Added 6.52% |
$763,021
$34.03 p/Share
|
Mar 01
2016 |
|
CMCSA
|
Lawrence J Salva
EVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 18,732 Reduced 21.03% |
$1,105,375
$59.01 p/Share
|
Mar 01
2016 |
|
CMCSA
|
Lawrence J Salva
EVP & Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct | 33,222 Added 27.17% |
$527,898
$15.89 p/Share
|
Mar 01
2016 |
|
CMCSA
|
Lawrence J Salva
EVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct | 48,044 Reduced 68.31% |
$2,837,959
$59.07 p/Share
|
Mar 01
2016 |
|
TMO
|
Seth H Hoogasian
Sr. VP & Retiring Gen. Counsel |
SELL
Open market or private sale
|
Direct | 2,951 Reduced 7.4% |
$398,385
$135.0 p/Share
|
Mar 01
2016 |
|
SYNH
|
Michael Gibertini |
SELL
Open market or private sale
|
Direct | 9,000 Reduced 15.99% |
$358,650
$39.85 p/Share
|
Mar 01
2016 |
|
SYNH
|
Michael Gibertini |
BUY
Exercise of conversion of derivative security
|
Direct | 9,000 Added 13.79% |
$76,050
$8.45 p/Share
|
Mar 01
2016 |
|
SNX
|
Dennis Polk
Hyve Solutions Executive |
SELL
Open market or private sale
|
Direct | 1,000 Reduced 1.4% |
$94,560
$94.56 p/Share
|
Mar 01
2016 |
|
SNX
|
Simon Leung
Chief Business Officer |
SELL
Open market or private sale
|
Direct | 1,000 Reduced 3.35% |
$94,720
$94.72 p/Share
|
Mar 01
2016 |
|
SPOK
|
Vincent D Kelly
President & CEO |
SELL
Open market or private sale
|
Indirect | 5,000 Reduced 1.49% |
$88,350
$17.67 p/Share
|
Mar 01
2016 |
|
IRDM
|
Thomas C Canfield |
BUY
Open market or private purchase
|
Direct | 5,000 Added 2.55% |
$34,750
$6.95 p/Share
|
Mar 01
2016 |
|
IOGPQ
|
R Brian Hanson
President & CEO |
BUY
Open market or private purchase
|
Direct | 20,000 Added 15.36% |
$76,800
$3.84 p/Share
|
Mar 01
2016 |
|
IOGPQ
|
R Brian Hanson
President & CEO |
BUY
Grant, award, or other acquisition
|
Direct | 50,000 Added 35.67% |
-
|
Mar 01
2016 |
|
IOGPQ
|
Steven Bate
EVP & CFO |
BUY
Open market or private purchase
|
Direct | 10,000 Added 14.62% |
$42,000
$4.2 p/Share
|
Mar 01
2016 |
|
IOGPQ
|
Steven Bate
EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct | 25,000 Added 34.05% |
-
|
Mar 01
2016 |
|
HON
|
Thomas A Szlosek
SVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 27,602 Reduced 30.3% |
$2,886,893
$104.59 p/Share
|
Mar 01
2016 |
|
HON
|
Thomas A Szlosek
SVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct | 54,206 Added 37.31% |
$5,669,405
$104.59 p/Share
|
Mar 01
2016 |
|
ABBV
|
Timothy J. Richmond
EVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct | 10,792 Reduced 14.02% |
$593,560
$55.0 p/Share
|
Mar 01
2016 |
|
MA
|
Andrea L Forster
Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct | 2,276 Added 15.31% |
-
|
Mar 01
2016 |
|
PLXS
|
Dean A Foate
Director |
SELL
Open market or private sale
|
Direct | 7,000 Reduced 3.73% |
$257,600
$36.8 p/Share
|
Mar 01
2016 |
|
PLXS
|
Dean A Foate
Director |
BUY
Exercise of conversion of derivative security
|
Direct | 7,000 Added 3.59% |
$155,190
$22.17 p/Share
|
Mar 01
2016 |
|
KMF
|
Voya Financial, Inc.
> 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect | 50,000 Reduced 12.5% |
$1,287,500
$25.75 p/Share
|
Feb 29
2016 |
|
AMT
|
Samme L Thompson |
SELL
Open market or private sale
|
Direct | 10,000 Reduced 35.57% |
$904,300
$90.43 p/Share
|
Feb 29
2016 |
|
AMT
|
Samme L Thompson |
BUY
Exercise of conversion of derivative security
|
Direct | 10,000 Added 26.24% |
$315,000
$31.5 p/Share
|
Feb 29
2016 |
|
AMT
|
Carolyn Katz
Director |
BUY
Exercise of conversion of derivative security
|
Direct | 10,000 Added 32.47% |
$315,000
$31.5 p/Share
|
Feb 29
2016 |
|
HON
|
Darius Adamczyk
Director |
SELL
Payment of exercise price or tax liability
|
Direct | 5,379 Reduced 16.97% |
$553,499
$102.9 p/Share
|
Feb 29
2016 |
|
HON
|
Darius Adamczyk
Director |
BUY
Exercise of conversion of derivative security
|
Direct | 10,572 Added 25.01% |
$1,087,859
$102.9 p/Share
|
Feb 29
2016 |
|
HON
|
Thomas A Szlosek
SVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 5,378 Reduced 12.73% |
$553,396
$102.9 p/Share
|
Feb 29
2016 |
|
HON
|
Thomas A Szlosek
SVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct | 10,572 Added 20.01% |
$1,087,859
$102.9 p/Share
|
Feb 29
2016 |
|
CVS
|
Jonathan C Roberts
EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct | 16,748 Added 15.39% |
$1,627,403
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Andrew Sussman
EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct | 1,675 Added 17.11% |
$162,760
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Andrew Sussman
EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct | 5,024 Added 26.57% |
$488,182
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Larry J Merlo
Director |
BUY
Grant, award, or other acquisition
|
Direct | 61,412 Added 21.59% |
$5,967,404
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
David M Denton
EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct | 16,748 Added 11.47% |
$1,627,403
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Troyen A Brennan
EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct | 14,515 Added 15.97% |
$1,410,423
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Thomas M Moriarty
EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct | 13,957 Added 37.43% |
$1,356,202
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Helena Foulkes
EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct | 8,932 Added 17.85% |
$867,922
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Lisa Bisaccia
Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct | 8,932 Added 22.98% |
$867,922
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Stephen J Gold
EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct | 7,816 Added 27.97% |
$759,481
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Eva C Boratto
EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct | 1,415 Added 6.23% |
$137,496
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
Eva C Boratto
EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct | 2,233 Added 7.2% |
$216,981
$97.17 p/Share
|
Feb 29
2016 |
|
CVS
|
J. David Joyner
EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct | 5,582 Added 8.17% |
$542,403
$97.17 p/Share
|
Feb 29
2016 |
|
ABT
|
Jean Yves Pavee
Senior Vice President |
SELL
Payment of exercise price or tax liability
|
Direct | 2,280 Reduced 5.69% |
$90,106
$39.52 p/Share
|
Feb 29
2016 |
|
ABT
|
Jean Yves Pavee
Senior Vice President |
BUY
Grant, award, or other acquisition
|
Direct | 11,394 Added 22.13% |
-
|
Feb 29
2016 |
|
ABT
|
Jean Yves Pavee
Senior Vice President |
SELL
Open market or private sale
|
Direct | 1,665 Reduced 4.4% |
$65,318
$39.23 p/Share
|
Feb 29
2016 |
|
ABT
|
Michael J Warmuth
Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct | 4,807 Reduced 6.94% |
$189,973
$39.52 p/Share
|
Feb 29
2016 |
|
ABT
|
Michael J Warmuth
Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct | 24,033 Added 25.77% |
-
|
Feb 29
2016 |
|
ABT
|
Michael J Warmuth
Executive Vice President |
SELL
Open market or private sale
|
Direct | 9,399 Reduced 14.59% |
$365,057
$38.84 p/Share
|
Feb 29
2016 |
|
ABT
|
Miles D White
EXECUTIVE CHAIRMAN |
SELL
Payment of exercise price or tax liability
|
Direct | 70,354 Reduced 4.6% |
$2,780,390
$39.52 p/Share
|
Feb 29
2016 |